ArticleCirculation reports2020
Empagliflozin Administration Can Decrease the Dose of Loop Diuretics and Prevent the Exacerbation of Renal Tubular Injury in Patients With Compensated Heart Failure Complicated by Diabetes.
Article in Circulation reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- The impact of sodium-glucose co-transporter-2 inhibitors on serum sodium and potassium in patients with Heart Failure: a systematic review and meta-analysis.BMC cardiovascular disorders · 2025Pooled it
- The effects of diuretic deprescribing in adult patients: A systematic review to inform an evidence-based diuretic deprescribing guideline.British journal of clinical pharmacology · 2025Pooled it
- Review
- Pericoronary adipose tissue: potential for pathological diagnosis and therapeutic applications.Cardiovascular intervention and therapeutics · 2025Review
- Empagliflozin and Right-Sided Heart Failure: A Comprehensive Review of Emerging Evidence and Clinical Perspectives.Cureus · 2025Review
- Combination of SGLT2 Inhibitors and Loop Diuretics in the Treatment of Heart Failure.Journal of personalized medicine · 2025Article
- Contemporary Use of Sodium Glucose Co-Transporter 2 Inhibitors in Hospitalized Heart Failure Patients: A "Real-World" Experience.Journal of clinical medicine · 2024Article
- Renoprotective effect of chronic treatment with sodium-glucose cotransporter 2 inhibitors and its associated factors in Japanese patients with chronic heart failure and diabetes.International journal of cardiology. Heart & vasculature · 2022Article
- Effects of Empagliflozin on Diuretics Reduction in Outpatient Heart Failure Patients.International journal of heart failure · 2022Article
- Article
- Effect of Empagliflozin in Preventing Progression of Renal Dysfunction in Diabetic Patients With Compensated Heart Failure - Reply.Circulation reports · 2021Article
- Effect of Empagliflozin in Preventing Progression of Renal Dysfunction in Diabetic Patients With Compensated Heart Failure.Circulation reports · 2021Article
- Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?International journal of heart failure · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.